IL250511D0 - Solid state forms of ibrutinib - Google Patents

Solid state forms of ibrutinib

Info

Publication number
IL250511D0
IL250511D0 IL250511A IL25051117A IL250511D0 IL 250511 D0 IL250511 D0 IL 250511D0 IL 250511 A IL250511 A IL 250511A IL 25051117 A IL25051117 A IL 25051117A IL 250511 D0 IL250511 D0 IL 250511D0
Authority
IL
Israel
Prior art keywords
ibrutinib
solid state
state forms
forms
solid
Prior art date
Application number
IL250511A
Other languages
Hebrew (he)
Original Assignee
Assia Chemical Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US201462037366P priority Critical
Priority to US201562130828P priority
Priority to PCT/US2015/045070 priority patent/WO2016025720A1/en
Application filed by Assia Chemical Ind Ltd filed Critical Assia Chemical Ind Ltd
Publication of IL250511D0 publication Critical patent/IL250511D0/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
IL250511A 2014-08-14 2017-02-08 Solid state forms of ibrutinib IL250511D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US201462037366P true 2014-08-14 2014-08-14
US201562130828P true 2015-03-10 2015-03-10
PCT/US2015/045070 WO2016025720A1 (en) 2014-08-14 2015-08-13 Solid state forms of ibrutinib

Publications (1)

Publication Number Publication Date
IL250511D0 true IL250511D0 (en) 2017-03-30

Family

ID=53901181

Family Applications (1)

Application Number Title Priority Date Filing Date
IL250511A IL250511D0 (en) 2014-08-14 2017-02-08 Solid state forms of ibrutinib

Country Status (5)

Country Link
US (1) US10035802B2 (en)
EP (1) EP3180343A1 (en)
CA (1) CA2958139A1 (en)
IL (1) IL250511D0 (en)
WO (1) WO2016025720A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6236071B2 (en) 2012-06-04 2017-11-22 ファーマサイクリックス エルエルシー Crystal form of breton-type tyrosine kinase inhibitor
TWI632912B (en) 2015-03-03 2018-08-21 製藥公司 Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor
RU2017133663A (en) * 2015-03-03 2019-04-03 Др. Редди'С Лабораторис Лимитед Polymorphes of ibrutinibe
GB2558514A (en) * 2016-02-09 2018-07-18 Azad Pharmaceutical Ingredients Ag Process for the synthesis of stable amorphous ibrutinib
CZ2016276A3 (en) 2016-05-11 2017-11-22 Zentiva, K.S. Solid forms of the ibrutinib free base
CN106008529A (en) * 2016-08-08 2016-10-12 上海工程技术大学 Ibrutinib solvate and preparation method thereof
US10183024B2 (en) 2016-12-02 2019-01-22 Apotex Inc. Crystalline forms of ibrutinib
WO2019070698A1 (en) 2017-10-02 2019-04-11 Johnson Matthey Public Limited Company Novel forms of ibrutinib
WO2019138326A1 (en) * 2018-01-09 2019-07-18 Dr. Reddy's Laboratories Limited Solid forms of ibrutinib
WO2019195827A1 (en) 2018-04-06 2019-10-10 Johnson Matthey Public Limited Company Novel form of ibrutinib
WO2019213184A1 (en) 2018-05-03 2019-11-07 Juno Therapeutics, Inc. Combination therapy of a chimeric antigen receptor (car) t cell therapy and a kinase inhibitor
EP3575300A1 (en) 2018-05-31 2019-12-04 Apotex Inc. Novel crystalline forms of ibrutinib
US10688050B1 (en) 2018-12-21 2020-06-23 Synthon B.V. Pharmaceutical composition comprising ibrutinib
EP3669867A1 (en) 2018-12-21 2020-06-24 Synthon B.V. Pharmaceutical composition comprising ibrutinib

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0622277A2 (en) 2006-09-22 2011-08-09 Pharmacyclics Inc compound, pharmaceutical composition and inhibited tyrosine kinase
JP6236071B2 (en) 2012-06-04 2017-11-22 ファーマサイクリックス エルエルシー Crystal form of breton-type tyrosine kinase inhibitor
CN103694241A (en) 2013-11-27 2014-04-02 苏州晶云药物科技有限公司 Novel crystal form A of PCI-32765 and preparation method thereof
CN106008521A (en) * 2014-01-29 2016-10-12 苏州晶云药物科技有限公司 New crystal form of ibrutinib and preparation method thereof

Also Published As

Publication number Publication date
WO2016025720A1 (en) 2016-02-18
CA2958139A1 (en) 2016-02-18
EP3180343A1 (en) 2017-06-21
US10035802B2 (en) 2018-07-31
US20170226114A1 (en) 2017-08-10

Similar Documents

Publication Publication Date Title
HK1215097A1 (en) Continuity
HK1217861A1 (en) Wifi-coordinated laa-lte
GB201413018D0 (en) Beyond 1A
IL246902D0 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
IL251584D0 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
GB201419865D0 (en) Solution
GB201410907D0 (en) No details
HK1244728A1 (en) Intranasal administration
IL246785D0 (en) Benzimidazol-2-amines as midh1 inhibitors
GB201419094D0 (en) Anti-TIM-3-antibodies
IL257026D0 (en) Solid state forms of eluxadoline
HK1226398A1 (en) Benzimidazol-2-amines as midh1 inhibitors
IL250891D0 (en) Smyd inhibitors
ZA201700880B (en) Polymorphs of selinexor
SG11201609265RA (en) Characterizing states of subject
IL254655D0 (en) Co-crystals of ibrutinib
IL248895D0 (en) Phosphatidylinositol -kinase inhibitors
SG11201701322WA (en) Special effects techniques
IL250511D0 (en) Solid state forms of ibrutinib
IL238537D0 (en) Multi-task frisbee-umbrella
AU357930S (en) Wristwatch
GB2528557B (en) Soundbar
GB201516146D0 (en) None
AU359704S (en) Case
AU361515S (en) Dishrack